亚洲中文久久精品无码mp4,AV无码人妻一区二区三区

Chongqing Yili Pharmaceutical Technology
Serving The Public Health
Professional and Rigorous

Sales network covering most cities across the country

Successfully registered MAs 5

MA applications 8

R&D stage 6
Honest and Win-win Cooperation
We are looking forward to cooperate with customers to create the future.

About Yili Pharmaceutical Technology

Chongqing Yili Pharmaceutical Technology Co., Ltd. was established in 2019, located in Nanan District, Chongqing, is a MAH certified company with drug production license (Class B). Covering Beijing Yili Technology Co., LTD., Chongqing Fangzhou Pharmaceutical Co., LTD., the company focuses on the research and development of chemical drugs and biological products, and expands the field of pharmaceutical sales. It has developed into a comprehensive pharmaceutical enterprise integrating pharmaceutical research and development, production and distribution. After several years of business exploration, the company has carried out research and development layout of innovative drugs and high-tech barriers generic drugs in the core medical field through independent development, external introduction, project cooperation and other ways. At present, the company has a national class A new drug, the first imitation drug. At present, the company holds a total of 5 approvals, 8 products to be approved, 6 varieties in research, and 11 varieties sold by other manufacturers.

Product Center

< prev next >

Company profile
Company size
Corporate culture
Medical research
Corporate image

Multiple and simultaneous

Have the courage to create breakthroughs and apply new technologies

Company profile

Chongqing Yili Pharmaceutical Technology Co., Ltd. was established in 2019, located in Nanan District, Chongqing, is a MAH certified company with drug production license (Class B). Covering Beijing Yili Technology Co., LTD., Chongqing Fangzhou Pharmaceutical Co., LTD., the company focuses on the research and development of chemical drugs and biological products, and expands the field of pharmaceutical sales. It has developed into a comprehensive pharmaceutical enterprise integrating pharmaceutical research and development, production and distribution. After several years of business exploration, the company has carried out research and development layout of innovative drugs and high-tech barriers generic drugs in the core medical field through independent development, external introduction, project cooperation and other ways. At present, the company has a national Class A new drug, the first imitation drug. At present, the company holds a total of 5 approvals, 8 products to be approved, 6 varieties in research, and 11 varieties sold by other manufacturers.

Company size

The company has a strong sales team, the existing sales staff of 100 people. In all regions of the country, there are special personnel responsible for following up the bidding, sales and after-sales services. Now it has gradually established a sales network covering 90% of the administrative regions of the country, the business covers nearly 70 cities, and the products are sold to 31 provinces (municipalities directly under the Central Government) and autonomous regions. Since its establishment in 2019, the company has maintained a strong momentum of growing annual sales revenue. The company has a professional team, can quickly achieve the target products in various provinces and bid, and quickly into the hospital sales. In 2022, under the background of domestic collection and epidemic control, the company achieved sales revenue of more than 1 billion yuan, an increase of nearly 20%, highlighting the company's marketing strength.

Corporate culture

The company has always adhered to the "integrity" business philosophy. Relying on technological innovation, a standardized unified service system has been developed to meet the needs of personalized market development.
Enterprise spirit: truth-seeking, unity, dedication, innovation;
Enterprise purpose: pay attention to quality, integrity-based;
Enterprise philosophy: Scientific management, integrity management;
Enterprise service: Customer first, heart service

Medical research

The company's research and development targets focus on solid slow-controlled preparations, injections, hormones and other varieties with technical thresholds. Covering oncology, anesthesiology, cardiovascular surgery, neurosurgery, gynecology, pediatrics and other departments. Gradually extend to clinical general medicine. In addition, according to the characteristics of its strong sales ability, the company focuses on research and development in the fields of specialty drugs, cardiovascular drugs, endocrine system drugs and special dosage forms for children. Strive to accumulate products in these areas and form a domestic competitive enterprise in sales.

Corporate image

The company has strong academic support and promotion ability, and through the current advantageous varieties to establish their own expert resources, and the main committee of the provinces can effectively interact, and with a number of domestic medical associations have in-depth cooperation. The professional team of academic promotion and efficient sales team are combined to provide good products and services for many terminal hospitals and customers throughout the country, and strive to create a rigorous and professional corporate image in the industry.